Galapagos NV: business update: http://t.co/6w1jppWE
posted 6 days ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
TiGenix (NYSE Euronext: TIG) announced today that further to the cGMP inspection by the Dutch authorities it has obtained the manufacturing authorization for human medicinal products for its European manufacturing plant in Sittard-Geleen in the Netherlands. read more
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that it has resubmitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin intravitreal injection, 2.5 mg/mL, for the treatment of symptomatic Vitreomacular Adhesion (VMA) including macular hole. read more
Devgen nv (Euronext Brussels: DEVG) today announces the successful completion of the first sales season of its first hybrid pearl millet seed adapted to all pearl millet growing areas in India. read more
Devgen nv (Euronext Brussels: DEVG) today announces the successful conclusion of farmer trials in India of two new premium hybrid rice varieties. Sales of these new products start in the upcoming planting season beginning in May 2012. read more
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the FDA intended to grant its recently-submitted ocriplasmin BLA (Biological License Application) for Priority Review. The FDA grants Priority Review designation to drugs that may offer major advances in treatment, or provide a treatment where no adequate therapy exists. The FDA has a goal of completing a Priority Review in just six months. read more
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it has acquired the rights to develop and market Resolor® (prucalopride) in the United States (US) in an agreement with Janssen Pharmaceutica N.V. Terms of the agreement have not been disclosed. read more
BD (Becton, Dickinson and Company), een toonaangevend bedrijf in medische technologie dat wereldwijd actief is, heeft de lancering bekendgemaakt van een nieuwe I.V. veiligheidskatheter. De BD Insyte™ Autoguard™ BC met bloedcontroletechnologie vermindert het risico op blootstelling aan bloed met 95%. read more
